The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.
M. Persano, A. Casadei-Gardini, L. Fornaro et al.· Cancer· 0 citations
Findings support the efficacy of adjuvant ICIs across multiple solid tumors, with consistent improvements in DFS/RFS and a significant pooled OS benefit, and exploratory meta-regression suggested that tumor type may contribute to between-study heterogeneity.
M. Polito, L. Sisca, D. Caruso et al.· Frontiers in Oncology· 0 citations
The current evidence on the clinical applications of circulating tumor DNA in muscle-invasive bladder cancer is summarized, including its role in prognosis, treatment selection, and surveillance, and future perspectives for integrating molecular monitoring into personalized cancer care are discussed.
M. Polito, L. Sisca, D. Caruso et al.· Cancers· 0 citations
Preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use.
K. Sridharan, Mattia Alberto Di Civita, G. Sivaramakrishnan et al.· Expert Review of Anticancer...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
